Table 4.
Published experience of systemic therapy in metastatic/locally advance SFT
| Pts | RR with RECIST | RR with Choi | OS (mos) | PFS (mos) | |
|---|---|---|---|---|---|
| Sunitinib (Stacchiotti) | 31 | 6.4% | NR | 16.0 | 6.0 |
| Sorafenib (FSG) | 5 | 0% | NR | 19.7 | NR |
| Antiangiogenic drugs (Levard) | 10 | 0% | NR | NR | 5.1 |
| Temozolamide and Bevacizumab (Park) | 14 | NR | 79% | NR | 9.7 |
| Dacarbazine (Stacchiotti) | 8 | 37.5% | NR | NR | 7.0 |
| Anthracycline (Costantinidou) | 17 | 5.8% | NR | 14.6 | 4.2 |
| Chemotherapy (Levard) | 23 | 9% | NR | NR | 5.2 |
| Pazopanib (present study) | 13 | 9% | 46% | 13.3 | 4.7 |
(mos = months, NR = not reported, pts = number of patients, RR = response rate).